Program
Immunoconjugates
Also written as “Antibody-drug conjugate (ADC)”, “Antibody-Drug Conjugate” and “Dose Escalation, MEDI2228, ADC (antibody drug conjugate)”.
Its studies are mostly in Sarcoma · Neoplasms · Multiple Myeloma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Adcendo ApS | 11 open or running | phase 2since Jan 16, 2025 | Jan 16, 2025 | Feb 27, 2029phase 2 · NCT06797999 |
| AstraZeneca | 10 open or running | phase 1since Mar 17, 2018 | Mar 17, 2018 | none ahead |
| MBrace Therapeutics | 11 open or running | phase 2since Aug 1, 2023 | Aug 1, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 17, 2018First study: phase 1 study in Multiple MyelomaNew to AstraZenecaAstraZeneca · NCT03489525 · 107 enrolled · United States, Australia, Greece and more
- Aug 1, 2023MBrace Therapeutics's first study: phase 2 study in NeoplasmsNew to MBrace TherapeuticsMBrace Therapeutics · NCT06014658 · 130 planned · United States
- Jan 16, 2025Adcendo ApS's first study: phase 2 study in SarcomaNew to Adcendo ApSAdcendo ApS · NCT06797999 · 270 planned · United States, Belgium, France and more
Ahead
- Feb 27, 2029Primary completion: phase 2 study in SarcomaAdcendo ApS · NCT06797999
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06797999Sarcoma · United States, Belgium, France and more | 2 | Recruiting | Adcendo ApS | Feb 27, 2029 | 270 |
| NCT06014658Neoplasms · United States | 2 | Recruiting | MBrace Therapeutics | Jul 2026 | 130 |
| NCT03489525Multiple Myeloma · United States, Australia, Greece and more | 1 | Completed | AstraZeneca | Mar 21, 2022 | 107 |
How it is read
Names in the registry
- “Antibody-drug conjugate (ADC)”, 1 entry
- “Antibody-Drug Conjugate”, 1 entry
- “Dose Escalation, MEDI2228, ADC (antibody drug conjugate)”, 1 entry
- “Dose Expansion, MEDI2228, ADC (antibody drug conjugate)”, 1 entry
Conditions, from the studies’ own filings
- Sarcoma, 1 study
- Neoplasms, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.